FibroScan ® Study: Assessing Liver Fibrosis in Patients Using Methotrexate for Psoriasis
| Status: | Recruiting |
|---|---|
| Conditions: | Psoriasis |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/31/2019 |
| Start Date: | February 10, 2019 |
| End Date: | December 31, 2023 |
| Contact: | Kory Schrom, MD |
| Email: | Kory.Schrom@UHhospitals.org |
| Phone: | 216-844-5728 |
A Prospective, Validation Study of FibroSURE™ and FibroScan® as Screening, Detection, and Monitoring Alternatives to Liver Biopsy for Methotrexate-induced Hepatic Fibrosis and Cirrhosis in Patients With Psoriasis
The purpose of this study is to validate FibroScan and FibroSURE™ as equal or superior
alternatives to liver biopsy for the monitoring and detection of methotrexate-induced hepatic
fibrosis and cirrhosis in patients with moderate-to-severe psoriasis.
alternatives to liver biopsy for the monitoring and detection of methotrexate-induced hepatic
fibrosis and cirrhosis in patients with moderate-to-severe psoriasis.
The goals of this study are to validate FibroScan and FibroSURE™ as equal or superior
alternatives to liver biopsy. The goal is to evaluate the monitoring and detection of
methotrexate-induced hepatic fibrosis and cirrhosis in patients with moderate-to-severe
psoriasis.
alternatives to liver biopsy. The goal is to evaluate the monitoring and detection of
methotrexate-induced hepatic fibrosis and cirrhosis in patients with moderate-to-severe
psoriasis.
Inclusion Criteria:
- Male or female greater than or equal to 18 years of age
- Must have a diagnosis of moderate-to-severe psoriasis
- Newly starting methotrexate
Exclusion Criteria:
- Allergy to methotrexate
- History of chronic alcohol abuse
- Diagnosis of liver disease
We found this trial at
1
site
Click here to add this to my saved trials
